MCID: OLG006
MIFTS: 38

Oligoastrocytoma

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Oligoastrocytoma

MalaCards integrated aliases for Oligoastrocytoma:

Name: Oligoastrocytoma 49 55 28
Mixed Oligoastrocytoma 55 69
Mixed Oligodendroglioma-Astrocytoma 69
Oligoastrocytoma Mixed 51
Moa 55

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Orphanet 55 ORPHA251656
UMLS via Orphanet 70 C0280793
ICD10 via Orphanet 33 C71.9
UMLS 69 C0547065

Summaries for Oligoastrocytoma

NIH Rare Diseases : 49 Oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass.  These brain cells are known as glial cells, which normally protect and support nerve cells in the brain.  Because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma.  Oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50.  The exact cause of this condition is unknown. Last updated: 10/5/2012

MalaCards based summary : Oligoastrocytoma, also known as mixed oligoastrocytoma, is related to astrocytoma and anaplastic oligodendroglioma, and has symptoms including seizures and headache. An important gene associated with Oligoastrocytoma is GFAP (Glial Fibrillary Acidic Protein). The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow.

Wikipedia : 72 Oligoastrocytomas are a subset of brain tumors that present with an appearance of mixed glial cell... more...

Related Diseases for Oligoastrocytoma

Diseases related to Oligoastrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 astrocytoma 30.1 GFAP MGMT
2 anaplastic oligodendroglioma 30.1 IDH2 MGMT
3 oligodendroglioma 29.7 GFAP IDH2 MGMT
4 glioblastoma 28.9 IDH2 MGMT
5 medulloblastoma 28.9 GFAP MGMT
6 anaplastic oligoastrocytoma 12.4
7 blood group, i system 10.1
8 glioma 10.1
9 pleomorphic xanthoastrocytoma 9.9 GFAP MGMT
10 spinal cord astrocytoma 9.9 GFAP MGMT
11 brain glioma 9.9 GFAP MGMT
12 ependymoma 9.9 GFAP MGMT
13 giant cell glioblastoma 9.9 GFAP MGMT
14 mixed glioma 9.9
15 leukemia 9.9
16 gliosarcoma 9.9 GFAP MGMT
17 pilocytic astrocytoma 9.8 GFAP MGMT
18 malignant glioma 9.8 GFAP MGMT
19 protoplasmic astrocytoma 9.7 GFAP IDH2
20 glioblastoma multiforme 9.7 GFAP MGMT
21 gemistocytic astrocytoma 9.7 GFAP IDH2
22 myelitis 9.7
23 cerebritis 9.7
24 multiple sclerosis 9.7
25 dystonia 9.7
26 mismatch repair cancer syndrome 9.7
27 paraplegia 9.7
28 leukemia, acute myeloid 9.7
29 myeloid leukemia 9.7
30 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
31 focal dystonia 9.7
32 cerebrospinal fluid leak 9.7
33 myelomeningocele 9.7
34 cysticercosis 9.7
35 dermatomyositis 9.7
36 opsoclonus-myoclonus syndrome 9.7
37 lymphoblastic leukemia 9.7
38 transverse myelitis 9.7
39 epilepsy 9.7
40 myoclonus 9.7
41 fibrillary astrocytoma 9.4 GFAP IDH2 MGMT
42 grade iii astrocytoma 9.4 GFAP IDH2 MGMT
43 brain cancer 9.4 GFAP IDH2 MGMT

Graphical network of the top 20 diseases related to Oligoastrocytoma:



Diseases related to Oligoastrocytoma

Symptoms & Phenotypes for Oligoastrocytoma

UMLS symptoms related to Oligoastrocytoma:


seizures, headache

Drugs & Therapeutics for Oligoastrocytoma

Drugs for Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Carmustine Approved, Investigational Phase 3 154-93-8 2578
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
6
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 tannic acid Approved, Nutraceutical Phase 3
11 Alkylating Agents Phase 3,Phase 2,Phase 1
12 Dermatologic Agents Phase 3,Phase 1,Phase 2
13 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
14 interferons Phase 3,Phase 1,Early Phase 1
15 Gastrointestinal Agents Phase 3,Phase 1,Early Phase 1
16 Antiviral Agents Phase 3,Phase 1,Early Phase 1
17 Interferon-alpha Phase 3
18
Histamine Phosphate Phase 3 51-74-1 65513
19
Serotonin Phase 3 50-67-9 5202
20 Serotonin Agents Phase 3
21 Serotonin Antagonists Phase 3
22 Neurotransmitter Agents Phase 3
23 Histamine Antagonists Phase 3
24 Histamine H1 Antagonists Phase 3
25 Anti-Allergic Agents Phase 3
26 Antipruritics Phase 3
27
Iodine Approved, Investigational Phase 2 7553-56-2 807
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
30
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
31
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
32
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
33
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
34
Hydroxyurea Approved Phase 2 127-07-1 3657
35
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
36 Thiotepa Approved, Investigational Phase 2 52-24-4 5453
37
Lenograstim Approved, Investigational Phase 2 135968-09-1
38
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
39
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
40
Nintedanib Approved Phase 2 656247-17-5 56843413
41
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 6251 453
42
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
43
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
44
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
45
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
46
Trametinib Approved Phase 2 871700-17-3 11707110
47
Dabrafenib Approved, Investigational Phase 2 44462760 44516822
48
Palbociclib Approved, Investigational Phase 2,Phase 1 571190-30-2 5330286 11431660 5005498
49
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
50
Acetaminophen Approved Phase 2 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 99)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
3 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
4 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
5 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Active, not recruiting NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
6 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
9 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2 Temozolomide
10 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
11 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
12 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
13 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
14 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
15 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
16 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 RAD001
17 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
18 Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma Completed NCT00041587 Phase 1, Phase 2 IL13-PE38QQR
19 Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma Completed NCT00024570 Phase 1, Phase 2 IL13-PE38QQR
20 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2 Imatinib Mesylate & Hydroxyurea
21 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2 Bevacizumab
22 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
23 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
24 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
25 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
26 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Completed NCT00671970 Phase 2 Bevacizumab and Erlotinib
27 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Recruiting NCT02530320 Phase 2 Palbociclib
28 Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Recruiting NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
29 Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting NCT02800486 Phase 2 Intra-arterial Cetuximab;Intra-arterial Mannitol
30 Everolimus With and Without Temozolomide in Adult Low Grade Glioma Recruiting NCT02023905 Phase 2 Everolimus;Temozolomide
31 Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG Recruiting NCT02684058 Phase 2 dabrafenib;trametinib
32 Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Recruiting NCT03180502 Phase 2 Temozolomide
33 A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas Recruiting NCT01986348 Phase 2 Selinexor
34 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
35 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Active, not recruiting NCT00033280 Phase 2 temozolomide
36 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Active, not recruiting NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
37 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Active, not recruiting NCT01635283 Phase 2
38 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
39 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
40 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
41 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
42 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2 Temozolomide and O6-Benzylguanine
43 Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas Terminated NCT00062504 Phase 2 Talampanel
44 Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors Terminated NCT00848523 Phase 2 Panobinostat
45 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Terminated NCT01110876 Phase 1, Phase 2 Vorinostat;Erlotinib;Temozolomide
46 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma Withdrawn NCT02977689 Phase 2 IDH305
47 Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II) Withdrawn NCT02369367 Phase 2 Irinotecan;Lenalidomide
48 Phase I/II Cabazitaxel for Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2 Cabazitaxel
49 Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor Unknown status NCT01985256 Phase 1
50 Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor Unknown status NCT01470794 Phase 1

Search NIH Clinical Center for Oligoastrocytoma

Genetic Tests for Oligoastrocytoma

Genetic tests related to Oligoastrocytoma:

# Genetic test Affiliating Genes
1 Oligoastrocytoma 28

Anatomical Context for Oligoastrocytoma

MalaCards organs/tissues related to Oligoastrocytoma:

38
Brain, Bone, Bone Marrow, Spinal Cord, Myeloid

Publications for Oligoastrocytoma

Articles related to Oligoastrocytoma:

(show top 50) (show all 85)
# Title Authors Year
1
Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. ( 27796734 )
2017
2
Multifocal and multicentric low-grade oligoastrocytoma in a young patient. ( 28523320 )
2017
3
Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity? ( 28419269 )
2017
4
Neurosurgery concepts: Key perspectives on intrathecal fluorescein for detecting intraoperative cerebrospinal fluid leak during endoscopic endonasal surgery, spinal intraarterial chemotherapy, oligoastrocytoma classification by in situ molecular genetics, and prenatal myelomeningocele closure and the need for cerebrospinal fluid shunt placement. ( 27857862 )
2016
5
Primary spinal cord anaplastic oligoastrocytoma presenting with paraplegia. ( 26851716 )
2016
6
Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery. ( 26995546 )
2016
7
Primary Spinal Oligoastrocytoma. ( 27092919 )
2016
8
A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. ( 27329275 )
2016
9
Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase. ( 27672647 )
2016
10
Focal seizure induced by preoperative navigated transcranial magnetic stimulation in a patient with anaplastic oligoastrocytoma. ( 28017645 )
2016
11
A rare case of oligoastrocytoma with atypical symptoms initially diagnosed as multiple sclerosis: A case report. ( 26893863 )
2016
12
Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma. ( 25864100 )
2015
13
Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate? ( 25555564 )
2015
14
Solitary "aggressive" leptomeningeal anaplastic oligoastrocytoma. ( 26318905 )
2015
15
Does morphological assessment have a role in classifying oligoastrocytoma as "oligodendroglial" vs. "astrocytic"? ( 26466141 )
2015
16
Primary spinal oligoastrocytoma mimicking longitudinally extensive transverse myelitis. ( 26590667 )
2015
17
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). ( 24812135 )
2014
18
High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. ( 24519516 )
2014
19
Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. ( 25489269 )
2014
20
Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. ( 25391968 )
2014
21
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. ( 25143301 )
2014
22
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
23
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. ( 24162809 )
2014
24
Farewell to oligoastrocytoma: response to letters. ( 25381649 )
2014
25
Mixed Glioma (Oligoastrocytoma) in the Brain ofA an African Hedgehog (Atelerix albiventris). ( 25172052 )
2014
26
Analysis of CIC-associated CpG-island methylation in oligoastrocytoma. ( 23521081 )
2013
27
Infratentorial low-grade oligoastrocytoma with aggressive clinical behavior in an adult: a case report with genetic characterization. ( 22752622 )
2013
28
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. ( 23486687 )
2013
29
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. ( 23896377 )
2013
30
Experiential auditory hallucinations due to chronic epileptic discharges after radiotherapy for oligoastrocytoma. ( 23774105 )
2013
31
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. ( 22588899 )
2012
32
Cerebellar low-grade oligoastrocytoma presenting with subarachnoid haemorrhage. ( 22665014 )
2012
33
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. ( 21069360 )
2011
34
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. ( 20556480 )
2011
35
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. ( 19876600 )
2010
36
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-. ( 20505301 )
2010
37
Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. ( 19225409 )
2009
38
Multi-focal cerebral oligoastrocytoma in a puppy. ( 19689673 )
2009
39
Anaplastic oligoastrocytoma in Turcot syndrome. ( 19495563 )
2009
40
Oligoastrocytoma of the brain in a hooded crane (Grus monacha). ( 19261644 )
2009
41
Autoimmunity manifesting as dermatomyositis associated with oligoastrocytoma and dendritic cell immunotherapy. ( 18443006 )
2008
42
A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. ( 18317968 )
2008
43
Malignant transformation of oligoastrocytoma: a case report. ( 18095133 )
2007
44
Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia. ( 17043901 )
2007
45
Intradural extramedullary spinal spread of oligoastrocytoma. ( 17582770 )
2007
46
Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. ( 17660801 )
2007
47
Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. ( 18077983 )
2007
48
Oligoastrocytoma presenting with intractable epilepsy. ( 17884756 )
2007
49
Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. ( 17431544 )
2007
50
Anaplastic oligodendroglioma and oligoastrocytoma. ( 17964027 )
2007

Variations for Oligoastrocytoma

Expression for Oligoastrocytoma

Search GEO for disease gene expression data for Oligoastrocytoma.

Pathways for Oligoastrocytoma

GO Terms for Oligoastrocytoma

Sources for Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....